Travere Therapeutics to Report Third Quarter 2024 Financial Results
Wells Fargo Upgrades Travere Therapeutic(TVTX.US) to Buy Rating, Announces Target Price $27
Wells Fargo Upgrades Travere Therapeutics to Overweight From Equalweight, Adjusts Price Target to $27 From $9
12 Health Care Stocks Moving In Thursday's After-Market Session
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday
Travere Therapeutics Receives Swiss Regulator's Temporary Marketing Approval for Kidney Disease Treatment
Express News | CSL Vifor and Travere Therapeutics Announce Swissmedic Approval of Filspari® (Sparsentan) for the Treatment of Iga Nephropathy
CSL Vifor and Travere Therapeutics Announce Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy
Scotiabank Initiates Travere Therapeutics at Sector Outperform With $23 Price Target
Travere Therapeutics To Present 11 Abstracts, Including One Late-breaking Abstract At Upcoming American Society Of Nephrology Kidney Week 2024 In San Diego, October 23-27
Evercore Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $30
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $20 to $41
Travere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Travere Therapeutics Shares Are Trading Higher After Wedbush Maintained an Outperform Rating on the Stock and Raised Its Price Target From $17 to $25.
Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $41
Express News | Travere Therapeutics Inc : Guggenheim Raises Target Price to $41 From $23
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $20
Leerink Partners Reiterates Outperform on Travere Therapeutics, Maintains $20 Price Target
CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $22
Travere Therapeutics Is Maintained at Overweight by Barclays